Director at Esperion Therapeutics (ESPR) receives 79,873-share equity award

Rhea-AI Filing Summary

CARROLL J MARTIN reported acquisition or exercise transactions in this Form 4 filing.

Esperion Therapeutics, Inc. director J. Martin Carroll received an equity grant of 79,873 shares of Common Stock as compensation. The shares were awarded at no cash cost per share and increase his direct holdings to 177,523 shares. The award vests in full on the earlier of May 28, 2027 or the company’s next annual meeting of stockholders following May 28, 2026.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider CARROLL J MARTIN

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	79,873	$0.00	--

Holdings After Transaction: Common Stock — 177,523 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares granted: 79,873 shares Award price per share: $0.0000 per share Total shares after grant: 177,523 shares +1 more

4 metrics

Shares granted 79,873 shares Compensation award of Common Stock

Award price per share $0.0000 per share Reported transaction price for grant

Total shares after grant 177,523 shares Direct holdings following transaction

Latest vesting date May 28, 2027 Latest possible full vesting date for award

Key Terms

Common Stock, Grant, award, or other acquisition, annual meeting of stockholders, vest

4 terms

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

annual meeting of stockholders financial

"the Issuer's next annual meeting of stockholders following May 28, 2026"

vest financial

"The awards vest in full on the earlier of (i) May 28, 2027"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CARROLL J MARTIN

(Last) (First) (Middle)

C/O ESPERION THERAPEUTICS, INC.

3891 RANCHERO DRIVE, SUITE 150

(Street)

ANN ARBOR MICHIGAN 48108

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Esperion Therapeutics, Inc. [ ESPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/28/2026		A		79,873(1)	A	$0	177,523	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The awards vest in full on the earlier of (i) May 28, 2027 and (ii) the Issuer's next annual meeting of stockholders following May 28, 2026.

Remarks:

	/s/ Sheldon L. Koenig, by power of attorney	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Esperion Therapeutics (ESPR) report for J. Martin Carroll?

Esperion Therapeutics reported that director J. Martin Carroll received a grant of 79,873 shares of Common Stock. This was a compensation-related award at no cash cost per share, increasing his direct holdings to 177,523 shares after the transaction.

Was the Esperion Therapeutics (ESPR) Form 4 transaction a purchase or a grant?

The Esperion Therapeutics Form 4 shows a grant or award acquisition, not an open-market purchase. Director J. Martin Carroll was awarded 79,873 Common Stock shares as compensation, recorded under transaction code A, with a reported price of $0.0000 per share.

How many Esperion Therapeutics (ESPR) shares does J. Martin Carroll hold after this award?

Following the award, J. Martin Carroll holds 177,523 shares of Esperion Therapeutics Common Stock directly. This total includes the newly granted 79,873 shares, reflecting his updated ownership position reported in the Form 4 filing after the compensation grant.

When do the newly granted Esperion Therapeutics (ESPR) shares vest for J. Martin Carroll?

The granted shares vest in full on the earlier of May 28, 2027, or Esperion Therapeutics’ next annual meeting of stockholders following May 28, 2026. This means vesting depends on whichever of those two corporate events occurs first.

What does transaction code A mean in the Esperion Therapeutics (ESPR) Form 4?

Transaction code A in the Esperion Therapeutics Form 4 indicates a grant, award, or other acquisition of shares. In this case, it records a compensation-related equity award of 79,873 Common Stock shares to director J. Martin Carroll, rather than a market transaction.